Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03300687

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

Sponsor: Frequency Therapeutics

Updated 7 times since 2017 Last updated: Apr 11, 2018 Started: May 30, 2017 Primary completion: Dec 12, 2017 Completion: Jan 18, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Hearing Loss and is currently completed. Frequency Therapeutics leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
May 2018 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Jan 2018 — May 2018 [monthly]

Active Not Recruiting EARLY_PHASE1

Status: Recruiting → Active Not Recruiting
Oct 2017 — Jan 2018 [monthly]

Recruiting EARLY_PHASE1

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Frequency Therapeutics

Data source: Frequency Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia